This is a heavily interactive web application, and JavaScript is required. Simple HTML interfaces are possible, but that is not what this is.
Post
Alberto Espay
albertoespay.bsky.social
did:plc:hord4uxurmhozizf5un5ko57
(3/9) Donanemab: In the 18 double-blind months, the CDR-SB score lowers by 1.6 (vs. 2.2 in placebo); in the subsequent 18 open-label months, the CDR-SB lowers 2.5 (4.1-1.6) –a 𝟱𝟲% 𝗳𝗮𝘀𝘁𝗲𝗿 𝗱𝗲𝗰𝗹𝗶𝗻𝗲 (2.5 -1.6 /1.6 * 100).
2025-08-28T15:10:00.048Z